GlaxoSmithKline PLC
29 April 2004
Issued: 29th April 2004, London
Results Announcement for the First Quarter 2004
GSK on track to deliver 2004 financial guidance
GlaxoSmithKline plc (GSK) today announces its results for the first quarter ended 31st March 2004. The full UK GAAP
results are presented under 'Profit and loss account' on page 6 and are summarised below.
FINANCIAL RESULTS*
Q1 2003
Q1 2004 (restated) Growth
£m £m CER% £%
Turnover 4,943 5,222 2 (5)
Business performance
Trading profit 1,562 1,796 (2) (13)
Profit before tax 1,576 1,763 1 (11)
Earnings per share 19.4p 21.6p 1 (10)
Statutory results
Trading profit 1,562 1,691 4 (8)
Profit before tax 1,576 1,658 7 (5)
Earnings per share 19.4p 20.3p 8 (4)
* The Group's practice is to discuss its results in terms of constant exchange rate (CER) growth. In
2004, the Group expects to report results on a statutory basis only. Growth rates are presented
comparing 2004 results both with 2003 business performance results and 2003 statutory results. All
commentaries compare 2004 results with 2003 business performance results in CER terms unless otherwise
stated. Results in 2003 have been restated following the implementation of UITF 17 (revised) and UITF
38. See 'Accounting for own shares' on page 5 and 'Accounting Presentation and Policies' on page 15
for fuller explanations of these matters.
Q1 2004 SUMMARY*
• Total pharmaceutical turnover increased 1%, despite significant erosion from Paxil generics.
Excluding sales of Paxil IR turnover grew 6% globally and 10% in the USA.
• Five key products, representing nearly 30% of pharmaceutical turnover, grew in strong double digits:
- Seretide/Advair for asthma (+22%)
- Avandia/Avandamet for diabetes (+18%)
- Lamictal for epilepsy/bi-polar disorder (+29%)
- Valtrex for herpes (+31%)
- Coreg for heart disease (+27%)
• GSK plans to launch several new products in the next 9 months including: Epivir/Ziagen for HIV,
Avandaryl for type 2 diabetes, and Vesicare for over-active bladder.
• Strong performance from the Consumer Healthcare business, with sales up 6% to £763 million.
• Weak US dollar significantly impacted performance in the quarter in sterling terms.
• Earnings per share (EPS) up 1% in the quarter. GSK remains on track to deliver EPS in 2004
(at constant exchange rates) at least in line with business performance EPS in 2003.
Commenting on the performance for the quarter and GSK's outlook, JP Garnier, Chief Executive Officer, said:
'GSK is off to a good start in this year of transition. The size and scope of our business and the strong
performance of key products, such as Advair for asthma and Avandia for diabetes, enabled us to overcome
substantial losses of sales to generic competitors in the first quarter. Excluding the impact of Paxil
generics US growth was estimated at 10 per cent. The next two quarters will continue to be challenging but
in the fourth quarter we expect to see a return to earnings growth for GSK.'
KEY PHARMACEUTICAL GROWTH DRIVERS
• GSK's number one product, Seretide/Advair, for the treatment of asthma and Chronic Obstructive
Pulmonary Disease (COPD) continues to grow strongly with sales up 22% to £581 million. In the USA,
sales rose 24% to £317 million. European and International sales were both up 18%.
The growth prospects for Advair were further strengthened with the US launch in the quarter of a new
indication for COPD and with FDA approval for the treatment of asthma in children above 4 years. GSK
also filed Seretide for approval in the treatment of asthma in Japan on 16th April.
• The Avandia family of diabetes treatments (Avandia and Avandamet) performed well with sales growing 18%
to £238 million. Reported US sales growth of 11% was adversely impacted by wholesaler stocking
patterns and underlying growth is estimated to be approximately 28%. Sales have benefited from the
recent launch of a higher strength Avandamet formulation.
European sales were up 83% to £22 million supported by an increased awareness of Avandia's benefits.
In addition Avandamet was approved in the EU in December 2003 and rollout of this new product has just
begun. International sales grew 43% to £31 million.
• The exceptionally strong growth of Lamictal continues, with sales up 29% to £153 million. In the USA,
Lamictal sales rose 39% to £91 million. US sales have benefited from Lamictal's new indication to
treat bi-polar disorder.
• Sales of Coreg, for the treatment of heart failure, grew by 27% to £94 million. Growth prospects for
the product were strengthened by data from the landmark COMET study which has recently been included in
promotional materials. This showed that Coreg reduced risks of death from a cardiovascular event by
20%, a heart attack by 30% and death from a stroke by 67% compared to Metoprolol.
On 13th April, GSK announced that it would acquire Sanofi-Synthelabo's injectable anti-thrombotic
agents Fraxiparine and Arixtra, conditional on Sanofi successfully completing its acquisition of
Aventis. These products would complement GSK's cardiovascular business.
• Valtrex (for genital herpes) sales rose 31% to £133 million driven by a strong performance in the USA
(sales up 38% to £86 million). Valtrex is the only treatment with an indication to reduce transmission
of genital herpes, supporting the strong efficacy profile of the product and its use in once-daily
therapy.
• Sales of GSK's HIV products were £348 million. Growth in Europe (+9%) and International markets (+12%)
was offset by lower sales in the USA (-8%). However reported US growth was impacted by stocking
patterns in the first quarter 2003; underlying percentage growth for the US franchise is estimated to
be in the low single digits.
• Demand for Levitra continued to build in the quarter. Estimated total sales for the product were
around £44 million (compared with £23 million in Q4 2003), giving a contribution to GSK's turnover of
£17 million. Total prescriptions in the United States increased by 34% in Q1 2004 compared to Q4 2003.
NEW LINE EXTENSIONS MITIGATE GENERIC COMPETITION
• Paxil CR performed very well in the quarter, with sales of £101 million (+37%). CR has maintained its
market share in the US anti-depressant market since the launch of generic Paxil and was recently
launched for the treatment of social anxiety disorder. Total sales of Seroxat/Paxil fell 36% to £291
million, with US sales down 48% due to the continuing impact of the launch of generic versions of Paxil
IR in September 2003.
• Wellbutrin sales rose 17% to £221 million, driven by the continued strong uptake of Wellbutrin XL which
now represents 44% of total branded and generic Wellbutrin (SR+XL) prescriptions. Generic competition
to the most frequently prescribed dosage form of Wellbutrin SR (150 mg) began in late March. This had
a limited impact on reported sales for the quarter, but will adversely affect future quarters.
REGIONAL PHARMACEUTICAL PERFORMANCE
• Turnover in the United States increased by 1% to £2.1 billion, despite the impact of generic
competition to Paxil IR which began in September 2003. Excluding Paxil IR, US turnover increased 10%
on a reported basis. Generic competition to Wellbutrin SR had only a limited impact on reported sales
for the quarter, but will adversely affect future quarters.
• European turnover of £1.2 billion, was unchanged compared with the first quarter 2003, with growth
impacted by price reductions in Germany and generic competition to Seroxat/Paxil, particularly in the
UK.
• In International markets good performances in Latin America (+12%) and Asia Pacific (+7%) were offset
by lower sales in Canada (-4%), affected by Paxil generics, and Japan (-1%), affected by a weak
rhinitis season.
NEW PRODUCT UPDATE
Over the next nine months GSK intends to launch and file several important new medicines:
2004 product launches
• Epivir/Ziagen, expected to be launched in the third quarter, will be the first once-daily combination
HIV treatment available in a single tablet. This new combination will offer a significant improvement
in patient convenience over other treatment options.
• The Avandia franchise is set to benefit from a new fixed-dose combination treatment called Avandaryl
also expected to be launched in the third quarter. This new convenient once-daily medication combines
Avandia with Aventis' Amaryl, a market leading sulphonylurea and will further extend the Avandia
'family' of treatments for type II diabetes.
• Following an FDA Approvable Letter in October 2003, Vesicare (solifenacin succinate), which GSK will
co-promote with Yamanouchi Pharma America, is expected to launch later this year. In clinical trials,
Vesicare once-daily compared to placebo was effective in improving the symptoms of over-active bladder
and was associated with a low incidence of dry mouth. Over-active bladder affects an estimated 17
million people in the USA.
2004 new product filings
• Filings will be made this year for new, convenient monthly oral and quarterly i.v. dosing regimens for
Boniva a potent oral bisphosphonate treatment for osteoporosis. Boniva is being co-developed by GSK
and Roche.
• Alvimopan, developed with Adolor Corporation, is expected to be filed this year for the management of
post-operative ileus, the gastrointestinal side effect which can affect millions of patients following
many types of surgery. Phase III data has shown that when compared with placebo, alvimopan accelerates
the recovery of gastrointestinal function and permits patients who have had abdominal surgery to leave
hospital earlier.
• Nelarabine for relapsed or refractory childhood T-cell leukaemia. Recent data for nelarabine in these
patients showed a complete remission rate of 47%, a response rate nearly five times better than any
agent has shown in a similar setting.
• In mid-2004 GSK plans to file a response to the FDA Approvable Letter related to the use of Requip for
Restless Legs Syndrome (RLS). Requip is expected to become the first product in the USA indicated for
the treatment of RLS, a neurological disorder that affects an estimated 8-10% of the US population.
• Building on its strong portfolio of vaccines, GSK plans to file for regulatory approval of three new
vaccines. In the USA, Boostrix will be filed as a booster vaccine to prevent diptheria, tetanus and
pertussis for adolescents and adults. Priorix Tetra, which builds on GSK's existing mumps, measles and
rubella vaccine with the addition of varicella protection, will be filed in Europe. Rotarix, a new
vaccine for the prevention of rotavirus gastroenteritis in young children, will be filed in Latin
American markets.
CONSUMER HEALTHCARE
Consumer Healthcare sales grew 6% to £763 million, reflecting strong demand for the Group's products in most European
(+8%) and International (+11%) markets. Sales in the USA were down 2%.
Oral care sales were up 6% to £260 million with growth across all regions. Growth in this category was driven by the
performance of the Aquafresh and Sensodyne brands.
Nutritional healthcare products grew 13% with strong growth in both Europe (+12%) and International (+16%) regions. In
the UK, Lucozade continued to gain sales. Horlicks in India accounted for most of the growth in International.
Over-the-counter medicine sales were £353 million (+2%). Strong performances in smoking control (+17%), boosted by
growth in Europe, and Panadol (+14%) in International markets, were partially offset by lower US sales of
dermatological products.
FINANCIAL REVIEW
Trading profit and earnings per share
Trading profit for Q1 2004 was £1,562 million, a 2% decline in CER terms (13% in sterling terms) compared with Q1 2003
business performance. Turnover growth was 2% in CER terms, but declined 5% in sterling terms, and this resulted in a
margin decline of 2.8 percentage points compared with Q1 2003. Net of currency movements the margin declined 1.2
percentage points, principally due to higher R&D expenditure and a higher cost of goods due to a less favourable
product mix, partially offset by lower manufacturing costs.
Other operating income was £35 million compared with an operating expense of £20 million in Q1 2003. The year on year
movement reflects lower provisions in 2004 for product liability and other claims partly offset by lower disposals of
equity investments in 2004.
EPS of 19.4 pence increased 1% in CER terms compared with Q1 2003 business performance EPS but declined 10% in sterling
terms. The adverse currency impact on EPS of 11% reflected the significant weakening of the US dollar relative to last
year.
Compared with Q1 2003 statutory results, which included merger and manufacturing restructuring costs and disposals of
businesses, EPS grew 8% in CER terms but declined 4% in sterling terms.
Currencies
The first quarter 2004 results are based on average exchange rates, principally £1/$1.83, £1/Euro 1.47 and £1/Yen 195.
The period-end exchange rates were £1/$1.84, £1/Euro 1.50 and £1/Yen 191. Since the period end the dollar has
strengthened and at 23rd April 2004 the exchange rates were £1/$1.77, £1/Euro 1.49 and £1/Yen 193. If exchange rates
were to hold at these levels for the remainder of 2004 the negative currency impact on earnings per share growth would
be approximately 8% for the full year.
Dividend
The Board has declared a first interim dividend of 10 pence per share. This compares with a dividend of 9 pence per
share for Q1 2003. The equivalent dividend receivable by ADR holders is 35.280 cents per ADS based on an exchange rate
of £1/$1.76398. The dividend will have an ex-dividend date of 12th May 2004 and will be paid on 1st July 2004 to
shareholders and ADR holders of record on 14th May 2004. The total dividend for the full year 2004 is expected to
increase in line with the 2003 increase of 1 penny per share.
Earnings guidance
In 2004, despite an expected substantial loss of sales due to generic competition to Paxil and Wellbutrin, GSK expects
to deliver EPS (at constant exchange rates) at least in line with business performance EPS in 2003. As the impact of
generics becomes less significant, GSK looks forward to a return to EPS growth in CER terms in 2005.
Share buy-back programme
In October 2002 GSK commenced a new £4 billion share buy-back programme. Of this new programme, £219 million was
accounted for in 2002, £980 million in 2003 and £279 million in Q1 2004. The exact amount and timing of future
purchases, and the extent to which repurchased shares will be held as Treasury shares rather than being cancelled, will
be determined by the company and is dependent on market conditions and other factors.
Accounting for own shares
In 2004, the Group has adopted UITF 17 (revised) and UITF 38 - see 'Accounting Presentation and Policies' on page 15.
As a result of the reclassification of own shares to equity shareholders' funds net assets at 31st December 2003
reduced by £2,661 million. Additionally, trading profit and profit before taxation in Q1 2003 have been reduced by £11
million and earnings have been reduced by £8 million.
US dollar global bond issue
GlaxoSmithKline issued its inaugural $2.5 billion US dollar global bond in the US market at the beginning of April.
The bond was issued in three tranches - 3, 10 and 30 years - in order to complement existing debt maturities and to
establish a liquid benchmark US yield curve for GSK's US dollar bonds. These funds will be used to repay preference
shares issued by a subsidiary, refinance 2004 debt maturities and for general corporate purposes.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to
improving the quality of human life by enabling people to do more, feel better and live longer. For company
information including a copy of this announcement and details of the company's updated product development pipeline,
visit GSK at www.gsk.com.
Enquiries: UK Media Martin Sutton (020) 8047 5502
David Mawdsley (020) 8047 5502
Chris Hunter-Ward (020) 8047 5502
US Media Nancy Pekarek (215) 751 7709
Mary Anne Rhyne (919) 483 2839
Patricia Seif (215) 751 7709
European Analyst / Investor Duncan Learmouth (020) 8047 5540
Philip Thomson (020) 8047 5543
Anita Kidgell (020) 8047 5542
US Analyst / Investor Frank Murdolo (215) 751 7002
Tom Curry (215) 751 5419
Brand names appearing in italics throughout this document are trade marks of GSK or associated companies with the
exception of Levitra, a trade mark of Bayer and Vesicare, a trade mark of Yamanouchi Pharmaceutical, which are used
under licence by the Group.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions
investors that any forward-looking statements or projections made by the company, including those made in this
Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those
projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the Operating and
Financial Review and Prospects in the company's Annual Report on Form 20-F for 2003.
PROFIT AND LOSS ACCOUNT
Three months ended 31st March 2004
Q1 2003
Merger,
Business restructuring
Q1 2004 Performance and disposal of Statutory 2003
Statutory Growth* (restated) businesses (restated) (restated)
£m CER% £m £m £m £m
--- --- --- --- --- ---
Turnover:
Pharmaceuticals 4,180 1 4,466 - 4,466 18,181
Consumer Healthcare 763 6 756 - 756 3,260
--- --- --- --- ---
TURNOVER 4,943 2 5,222 - 5,222 21,441
Cost of sales (1,024) 4 (1,019) (91) (1,110) (4,544)
--- --- --- --- ---
Gross profit 3,919 1 4,203 (91) 4,112 16,897
Selling, general and (1,726) 2 (1,777) (10) (1,787) (7,597)
administration
Research and development (631) 6 (630) (4) (634) (2,791)
--- --- --- --- ---
Trading profit:
Pharmaceuticals 1,451 (2) 1,690 (99) 1,591 5,933
Consumer Healthcare 111 11 106 (6) 100 576
--- --- --- --- ---
TRADING PROFIT 1,562 (2) 1,796 (105) 1,691 6,509
Other operating income/(expense) 35 (20) - (20) (133)
--- --- --- --- ---
Operating profit 1,597 1 1,776 (105) 1,671 6,376
Business disposals - - - - 5
Profits of associates 22 22 - 22 93
--- --- --- --- ---
Profit before interest 1,619 1,798 (105) 1,693 6,474
Net interest payable (43) (35) - (35) (161)
--- --- --- --- ---
PROFIT BEFORE TAXATION 1,576 1 1,763 (105) 1,658 6,313
Taxation (433) (476) 28 (448) (1,729)
--- --- --- --- ---
Profit after taxation 1,143 - 1,287 (77) 1,210 4,584
Minority interests (22) (20) - (20) (94)
Preference share dividends (2) (4) - (4) (12)
--- --- --- --- ---
EARNINGS 1,119 - 1,263 (77) 1,186 4,478
--- --- --- --- ---
EARNINGS PER SHARE 19.4p 1 21.6p 20.3p 77.1p
--- --- --- ---
Diluted earnings per share 19.4p 20.3p 76.9p
--- ---
Weighted average number of 5,768 5,838 5,838 5,806
shares (millions) --- --- --- ---
* Growth rates are calculated comparing Q1 2004 statutory results with Q1 2003 business performance results. Results
in 2003 have been restated following the implementation of UITF 17 (revised) and UITF 38 - see 'Accounting Presentation
and Policies' on page 15.
Appropriations of profit attributable to shareholders are set out under 'Appropriations' on page 10.
PHARMACEUTICAL TURNOVER
Three months ended 31st March 2004
Total USA Europe International
------------- -------------- ------------ ------------
£m CER% £m CER% £m CER% £m CER%
----- ----- ----- ----- ----- ----- ---- -----
RESPIRATORY 1,086 7 548 10 374 5 164 (1)
Seretide/Advair,
Flixotide/Flovent, Serevent 824 8 416 7 301 9 107 13
Seretide/Advair 581 22 317 24 211 18 53 18
Flixotide/Flovent 154 (9) 63 (18) 48 (6) 43 5
Serevent 89 (21) 36 (36) 42 (8) 11 16
Flixonase/Flonase 157 11 126 22 14 10 17 (38)
CENTRAL NERVOUS SYSTEM 914 (8) 612 (11) 193 (6) 109 6
Seroxat/Paxil 291 (36) 148 (48) 71 (27) 72 11
Paxil IR 190 (51) 48 (77) 71 (27) 71 10
Paxil CR 101 37 100 36 - - 1 >100
Wellbutrin 221 17 217 18 - - 4 (28)
Wellbutrin IR, SR 133 (30) 129 (29) - - 4 (36)
Wellbutrin XL 88 >100 88 >100 - - - -
Imigran/Imitrex 172 4 126 3 35 6 11 -
Lamictal 153 29 91 39 51 15 11 11
Requip 26 24 12 20 13 28 1 35
ANTI-VIRALS 562 6 271 6 183 6 108 5
HIV 348 - 172 (8) 140 9 36 12
Combivir 139 4 68 (2) 56 13 15 8
Trizivir 81 (8) 43 (16) 34 3 4 52
Epivir 71 4 33 (6) 29 16 9 15
Ziagen 38 (7) 18 (13) 15 (3) 5 14
Agenerase, Lexiva 9 9 6 17 2 2 1 (19)
Herpes 174 23 89 43 37 (2) 48 13
Valtrex 133 31 86 38 22 12 25 27
Zovirax 41 3 3 >100 15 (17) 23 1
Zeffix 30 4 3 34 5 24 22 (1)
ANTI-BACTERIALS 426 (4) 111 (8) 194 (5) 121 4
Augmentin 204 - 78 8 82 (12) 44 10
Augmentin IR 139 (3) 15 36 81 (13) 43 7
Augmentin ES, XR 65 5 63 3 1 >100 1 >100
Zinnat/Ceftin 63 2 4 (50) 41 9 18 10
METABOLIC 270 16 185 11 31 25 54 29
Avandia, Avandamet 238 18 185 11 22 83 31 43
VACCINES 240 (6) 55 (14) 101 (6) 84 1
Hepatitis 90 (11) 31 (23) 42 (5) 17 3
Infanrix/Pediarix 76 6 24 1 35 13 17 -
ONCOLOGY AND EMESIS 222 (1) 160 (2) 42 8 20 (9)
Zofran 180 10 132 12 32 8 16 (1)
Hycamtin 24 1 16 4 7 14 1 (51)
CARDIOVASCULAR AND UROGENITAL
200 27 129 34 49 16 22 15
Coreg 94 27 91 29 - - 3 (18)
Levitra 17 >100 11 - 5 93 1 -
Avodart 10 >100 6 >100 4 >100 - -
OTHER 260 (6) 22 (15) 79 (14) 159 (1)
Zantac 68 (14) 17 (17) 20 (22) 31 (7)
------------- -------------- ------------- -------------
4,180 1 2,093 1 1,246 - 841 3
------------- -------------- ------------- -------------
Pharmaceutical turnover includes co-promotion income.
CONSUMER HEALTHCARE TURNOVER
Three months ended 31st March 2004
Growth
£m CER%
--------- ---------
Over-the-counter medicines 353 2
Analgesics 85 12
Dermatological 45 (18)
Gastrointestinal 63 (2)
Respiratory tract 35 (1)
Smoking control 77 17
Natural wellness support 38 2
Oral care 260 6
Nutritional healthcare 150 13
--------- ---------
Total 763 6
--------- ---------
FINANCIAL REVIEW - PROFIT AND LOSS ACCOUNT
Trading profit
Q1 2003
------------------
Business
Q1 2004 performance
Statutory % of (restated) % of Growth
£m turnover £m turnover CER% £%
------ ------ ------ ------ ------ ----
Turnover 4,943 100.0 5,222 100.0 2 (5)
Cost of sales (1,024) (20.7) (1,019) (19.5) 4 -
Selling, general and administration (1,726) (34.9) (1,777) (34.0) 2 (3)
Research and development (631) (12.8) (630) (12.1) 6 -
------ ------ ------ ------ ------ ----
Trading profit 1,562 31.6 1,796 34.4 (2) (13)
------ ------ ------ ------ ------ ----
Overall the trading margin declined 2.8 percentage points and sterling trading profit declined 13% on a sterling
turnover decline of 5%. At constant exchange rates trading profit declined 2% and the margin declined 1.2 percentage
points principally reflecting a 4% increase in cost of sales and a 6% increase in R&D expenditure, while turnover grew
2%.
Cost of sales increased as a percentage of turnover by 1.2 percentage points. At constant exchange rates the increase
was 0.5 percentage points reflecting the loss of higher margin Paxil sales, partly offset by savings on manufacturing
costs.
SG&A as a percentage of turnover increased 0.9 percentage points. At constant exchange rates the increase was 0.2
percentage points. Selling, general and administration (SG&A) costs grew 2% (but declined 3% in sterling terms)
reflecting increased costs to support new product introductions, partly offset by cost saving initiatives.
Research and development (R&D) increased 6% (flat in sterling terms) reflecting increased clinical trial activity.
Pharmaceuticals R&D expenditure represented 14.6% of pharmaceutical turnover in the year.
Other operating income/(expense)
Other operating income/(expense) includes litigation costs and provisions relating to legal claims on withdrawn
products, product withdrawals and anti-trust matters, equity investment carrying value adjustments arising from stock
market price changes, royalty income, product disposals and equity investment sales.
Other operating income was £35 million compared with an operating expense of £20 million in Q1 2003. The year on year
movement reflects lower provisions in 2004 for product liability and other claims partly offset by lower disposals of
equity investments in 2004.
Taxation
The charge for taxation on profit amounting to £433 million represents an effective tax rate of 27.5%, which is the
expected rate for the year.
Transfer pricing issues are described in the 'Taxation' note to the Financial Statements included in the Annual Report
2003. Developments since the date of that report are as follows. With respect to the claims of the Internal Revenue
Service (IRS) for the years 1989-1996, which are described in the note, the company contested these claims for
additional taxes of $2.7 billion (£1.5 billion) and related interest of $2.5 billion (£1.4 billion) net of federal tax
relief by filing a petition in the US Tax Court on 2nd April 2004. A trial is not expected until 2005-2006. Similar
tax issues remain open for 1997 to date.
GSK continues to believe that the profits reported by its US subsidiaries for the period 1989 to date, on which it has
paid taxes in the United States, are more than sufficient to reflect the activities of its US operations. As stated in
previous updates, there continues to be a wide difference of views between the company and the IRS.
GlaxoSmithKline uses the best advice in determining its transfer pricing methodology and in seeking to manage transfer
pricing issues to a satisfactory conclusion and, on the basis of external professional advice, continues to believe
that it has made adequate provision for the liabilities likely to arise from open assessments. The ultimate liability
for such matters may vary significantly from the amounts provided and is dependent upon the outcome of litigation
proceedings and negotiations with the relevant tax authorities.
Earnings
Q1 2003 2003
Q1 2004 (restated) (restated)
£m £m £m
Net profit attributable to shareholders ---- ---- ----
Earnings 1,119 1,186 4,478
Adjustment for merger items, integration and restructuring costs and
disposal of businesses - 77 281
---- ---- ----
Adjusted earnings 1,119 1,263 4,759
---- ---- ----
pence pence pence
Earnings per share ---- ---- ----
Basic earnings per share 19.4 20.3 77.1
Adjustment for merger items, integration and restructuring costs and
disposal of businesses - 1.3 4.9
---- ---- ----
Adjusted earnings per share 19.4 21.6 82.0
---- ---- ----
Appropriations Q1 2003 2003
Q1 2004 (restated)
£m £m (restated)
£m
---- ---- ----
Net profit attributable to shareholders 1,119 1,186 4,478
Dividends (575) (524) (2,374)
---- ---- ----
Retained profit 544 662 2,104
---- ---- ----
Pence per 2004 Pence per 2003
share share
£m £m
Dividends ---- ---- ---- ----
First interim - payable 1st July 2004 10 575 9 524
Second interim 9 522
Third interim 9 520
Fourth interim 14 808
---- ----
41 2,374
---- ----
The number of shares in issue, excluding those held by the ESOP Trusts and those held as Treasury shares at 31st March
2004 was 5,749 million (31st March 2003: 5,821 million).
STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES
Q1 2003 2003
Q1 2004 (restated) (restated)
£m £m £m
---- ---- ----
PROFIT ATTRIBUTABLE TO SHAREHOLDERS 1,119 1,186 4,478
Exchange movements on overseas net assets (245) 151 113
Tax on exchange movements and unrealised gains (56) 44 (92)
Unrealised gains on equity investments - 1 7
---- ---- ----
TOTAL RECOGNISED GAINS AND LOSSES RELATING TO THE PERIOD 818 1,382 4,506
---- ----
Prior period adjustment - implementation of UITF 17 (revised) and UITF
38 368
----
TOTAL RECOGNISED GAINS AND LOSSES SINCE
31st DECEMBER 2003 1,186
----
SUMMARY STATEMENT OF CASH FLOW AND MOVEMENT IN NET DEBT
Three months ended 31st March 2004
Q1 2003 2003
Q1 2004 (restated) (restated)
£m £m £m
---- ---- ----
OPERATING PROFIT 1,597 1,671 6,376
Depreciation and other non-cash items 214 205 1,066
Increase in working capital (47) (139) (387)
Decrease in net liabilities (432) (74) (50)
---- ---- ----
NET CASH INFLOW FROM OPERATING ACTIVITIES 1,332 1,663 7,005
Dividends received from associates 2 - 1
Returns on investment and servicing of finance (89) (99) (231)
Taxation paid (271) (490) (1,917)
---- ---- ----
974 1,074 4,858
---- ---- ----
Purchase of tangible fixed assets (130) (153) (869)
Sale of tangible fixed assets 2 14 46
Purchase of intangible fixed assets (16) (37) (193)
---- ---- ----
(144) (176) (1,016)
Purchase of equity investments (4) (9) (63)
Sale of equity investments 3 42 125
---- ---- ----
Capital expenditure and financial investment (145) (143) (954)
---- ---- ----
Purchase of businesses - - (12)
Business disposals - - 3
Investment in joint ventures and associates - - (3)
---- ---- ----
Acquisitions and disposals - - (12)
---- ---- ----
Equity dividends paid (520) (527) (2,333)
---- ---- ----
NET CASH INFLOW BEFORE MANAGEMENT OF LIQUID RESOURCES AND
FINANCING 309 404 1,559
Issue of ordinary share capital 10 7 41
Proceeds from own shares for employee share options 4 1 26
Purchase of shares for cancellation (178) (241) (980)
Purchase of Treasury shares (90) - -
Redemption of preference shares issued by a subsidiary (440) - -
Other financing cash flows 33 63 82
Exchange movements (2) 50 (37)
Other non-cash movements (1) - (4)
---- ---- ----
(INCREASE)/DECREASE IN NET DEBT IN PERIOD (355) 284 687
NET DEBT AT BEGINNING OF PERIOD (1,648) (2,335) (2,335)
---- ---- ----
NET DEBT AT END OF PERIOD (2,003) (2,051) (1,648)
---- ---- ----
BALANCE SHEET
31st March 31st December
31st March 2003 2003
2004 (restated) (restated)
£m £m £m
---- ---- ----
Goodwill 133 159 143
Intangible fixed assets 1,642 1,704 1,697
Tangible fixed assets 6,261 6,695 6,441
Investments 295 306 294
---- ---- ----
FIXED ASSETS 8,331 8,864 8,575
---- ---- ----
Equity investments 165 152 164
Stocks 2,110 2,165 2,109
Debtors 6,837 6,417 6,897
Liquid investments 2,319 1,327 2,493
Cash at bank 667 903 962
---- ---- ----
CURRENT ASSETS 12,098 10,964 12,625
---- ---- ----
Loans and overdrafts (1,394) (1,327) (1,452)
Other creditors (7,154) (7,081) (7,019)
---- ---- ----
CREDITORS: amounts due within one year (8,548) (8,408) (8,471)
---- ---- ----
NET CURRENT ASSETS 3,550 2,556 4,154
---- ---- ----
TOTAL ASSETS LESS CURRENT LIABILITIES 11,881 11,420 12,729
---- ---- ----
Loans (3,595) (2,954) (3,651)
Other creditors (244) (220) (232)
---- ---- ----
CREDITORS: amounts due after one year (3,839) (3,174) (3,883)
---- ---- ----
PROVISIONS FOR LIABILITIES AND CHARGES (2,738) (3,027) (3,042)
---- ---- ----
NET ASSETS 5,304 5,219 5,804
---- ---- ----
Called up share capital 1,484 1,500 1,487
Share premium account 273 231 264
Other reserves (748) (906) (804)
Profit and loss account 4,033 3,612 4,112
---- ---- ----
EQUITY SHAREHOLDERS' FUNDS 5,042 4,437 5,059
Non-equity minority interest 49 570 503
Equity minority interests 213 212 242
---- ---- ----
CAPITAL EMPLOYED 5,304 5,219 5,804
---- ---- ----
RECONCILIATION OF MOVEMENTS IN EQUITY SHAREHOLDERS' FUNDS
Q1 2003 2003
Q1 2004 (restated) (restated)
£m £m £m
---- ---- ----
Equity shareholders' funds as previously reported 7,720 6,581 6,581
Prior period adjustment - implementation of UITF 17 (revised) and
UITF 38 (2,661) (2,741) (2,741)
---- ---- ----
Equity shareholders' funds at beginning of period as restated 5,059 3,840 3,840
Total recognised gains and losses for the period 818 1,382 4,506
Dividends (575) (524) (2,374)
Ordinary shares issued 10 7 41
Ordinary shares purchased and cancelled (179) (262) (980)
Ordinary shares purchased and held as Treasury shares (100) - -
Proceeds from own shares for employee share options 4 1 26
Credit in respect of employee share schemes 4 5 7
Exchange movements on goodwill written off to reserves 1 (12) (7)
---- ---- ----
Equity shareholders' funds 5,042 4,437 5,059
---- ---- ----
FINANCIAL REVIEW - CASH FLOW AND BALANCE SHEET
Cash flow
Operating cash flow was £1,332 million in Q1 2004. This represents a decrease of £331 million over Q1 2003 principally
due to lower operating profits combined with higher payments out of legal provisions. The operating cash flow is in
excess of the funds needed for the routine cash flows of tax, capital expenditure on tangible assets and dividend
payments, together amounting to £921 million. Receipts of £14 million arose from the exercise of share options: £4
million from shares held by the Employee Share Ownership Trusts (ESOTs) and £10 million from the issue of new shares.
In addition, £178 million was spent on purchasing the company's own shares for cancellation and £90 million on
purchasing Treasury shares. Preference shares issued by a subsidiary were redeemed in the quarter at a cost of £440
million, effectively replacing one form of funding with another.
Net assets
The book value of net assets decreased by £500 million from £5,804 million at 31st December 2003 to £5,304 million at
31st March 2004, principally arising from the refinancing of preference shares issued by a subsidiary with debt.
Fixed asset investments comprise investments in associates, joint ventures and long-term equity investments. The
carrying value of associates and equity investments was £460 million and the market value was £1,371 million.
Following the implementation of UITF 38 investments in own shares held by the ESOT are now shown as a deduction from
equity shareholders' funds.
Equity shareholders' funds
Equity shareholders' funds have been restated at 31st December 2003 to £5,059 million. At 31st March 2004 these had
decreased to £5,042 million. The decrease arises from retained earnings being offset by shares purchased and
cancelled, Treasury shares purchased and exchange movements on overseas net assets.
At 31st March 2004 the ESOTs held 176.5 million GSK ordinary shares, at a book value of £2,677 million and a market
value of £1,885 million, against the future exercise of share options and share awards, which have been deducted from
other reserves. At 31st March 2004 GSK also held 9.3 million shares as Treasury shares, at a cost of £100 million,
which have been deducted from profit and loss account reserves.
Legal proceedings
GlaxoSmithKline is involved in various legal and administrative proceedings, principally product liability,
intellectual property, anti-trust and governmental investigations and related private litigation. The outcome of
claims, legal proceedings and other matters in which the Group is involved cannot be predicted with any certainty.
Legal proceedings in which GlaxoSmithKline is involved are described in the 'Legal proceedings' note to the Financial
Statements and the 'Risk factors' in Operating and financial review and prospects included in the Annual Report 2003.
Developments since the date of the Annual Report are set out below.
With respect to the patent infringement action against Ranbaxy Pharmaceuticals in the US District Court for the
District of New Jersey regarding Ceftin, in March 2004 the court found the Group's patent valid but not infringed by
Ranbaxy and that there had been no inequitable conduct. Ranbaxy has been selling its generic version of Ceftin since
March 2002.
With respect to the patent revocation actions regarding Seretide brought by Cipla Ltd., Generics UK, Ivax and Arrow
Generics in the UK High Court, in March 2004 the Court ruled in favour of the claimants that under English law the
Group's UK combination patent for Seretide was not valid because it lacked an inventive step. The Group is evaluating
an appeal from that decision.
With respect to the Group's infringement action against Reddy-Cheminor and West-ward Pharmaceuticals, both
Reddy-Cheminor and West-ward have informed the Group that they are withdrawing their challenges to the compound patent
for ondansetron, the active ingredient in Zofran, amending their respective ANDAs and acknowledging that neither party
is seeking approval of its ANDA prior to the expiry of the Group's compound patent in July 2005 (taking into account an
expected extension for paediatric exclusivity). The Group, Reddy-Cheminor and West-ward will submit stipulations to
the US District Court for the District of New Jersey to remove the compound patent from the trial scheduled to commence
on 25th May 2004. Challenges by both Reddy-Cheminor and West-ward to method of use and process patents for Zofran
remain at issue and are to be litigated at the May trial. The Group continues to await a ruling on the method of use
patents from the US District Court for the District of Delaware following a trial with Teva Pharmaceuticals.
With respect to the appeals from the decisions of the US District Court for the Northern District of Illinois regarding
the Group's patent on the paroxetine hydrochloride hemihydrate formulation of Paxil, on 23rd April 2004 the Court of
Appeals for the Federal Circuit (CAFC) ruled that GSK's patent was infringed, but was invalid based upon 'public use'
in clinical trials prior to the filing date in the USA. This reversed rulings by the District Court that held the
patent was not infringed, but that the patent was valid because the use in clinical trials was a permissible
'experimental use'. The Group is evaluating an appeal from the CAFC decision.
With respect to patent infringement actions initiated by the Group regarding Wellbutrin SR/Zyban, since the date of the
Annual Report the Group has completed settlements of the actions filed against Eon Labs and Excel Pharmaceuticals.
With respect to the anti-trust litigation regarding Relafen, in April 2004 the US District Court for the District of
Massachusetts approved the Group's settlement with a class of direct purchasers. Litigation continues with the
remaining class of indirect purchasers in the same court. Trial is set for September 2004. The Group had made
provision for the Relafen anti-trust litigation in 2003.
Legal expenses incurred, relating to the defence of the Group's intellectual property, and litigation costs and
provisions relating to product liability claims on existing products, are charged to selling, general and
administration costs. Litigation costs and provisions relating to legal claims on withdrawn products and anti-trust
matters are charged to other operating income/expense. Provisions are made, after taking appropriate legal advice,
when a reasonable estimate can be made of the likely outcome of the dispute.
The ultimate liability for legal claims may vary from the amounts provided and is dependent upon the outcome of
litigation proceedings, investigations and possible settlement negotiations.
Developments with respect to tax matters are described in 'Taxation' on page 9.
EXCHANGE RATES
The results and net assets of the Group, as reported in sterling, are affected by movements in exchange rates between
sterling and overseas currencies. GSK uses the average of exchange rates prevailing during the period to translate the
results and cash flows of overseas Group subsidiary and associated undertakings into sterling and period end rates to
translate the net assets of those undertakings. The currencies which most influence these translations, and the
relevant exchange rates, are:
Q1 2004 Q1 2003 2003
Average rates: ---- ---- ----
£/US$ 1.83 1.60 1.64
£/Euro 1.47 1.49 1.45
£/Yen 195.00 191.00 191.00
Period end rates:
£/US$ 1.84 1.58 1.79
£/Euro 1.50 1.45 1.42
£/Yen 191.00 187.00 192.00
During Q1 2004 average sterling exchange rates were stronger against the US dollar and the Yen and weaker against the
Euro compared with the same period in 2003. Comparing Q1 2004 period end rates with Q1 2003 period end rates, sterling
was stronger against the US dollar, the Yen and the Euro.
ACCOUNTING PRESENTATION AND POLICIES
This unaudited Results Announcement for the three months ended 31st March 2004 is prepared in accordance with the
accounting policies expected to apply in 2004. These are unchanged from those set out in the Annual Report 2003,
except that during 2004 UITF Abstract 38 'Accounting for ESOP trusts' and related amendments to Abstract 17 'Employee
share schemes' have been implemented. UITF 38 changes the presentation of an entity's own shares held in an ESOP trust
from requiring them to be recognised as assets to requiring them to be deducted in arriving at shareholders' funds.
UITF 17 (revised) requires that the minimum expense should be the difference between the fair value of the shares at
the date of award and the amount that an employee may be required to pay for the shares (i.e. the intrinsic value of
the award).
Data for market share and market growth rates relate to the year ended 31st December 2003 (or later where available).
These are GSK estimates based on the most recent data from independent external sources, valued in sterling at relevant
exchange rates. Figures quoted for product market share reflect sales by GSK and licensees.
During the years 2000 to 2003, business performance was the primary performance measure used by management and was
presented after excluding merger items, integration and restructuring costs and disposals of businesses, as management
believed that exclusion of these items provided a better comparison of business performance for the periods presented.
In 2004, with the completion of these programmes, the Group expects to report results on a statutory basis only.
Growth rates are presented comparing 2004 results both with 2003 business performance results and 2003 statutory
results. Management considers that the comparison of 2004 statutory results with 2003 business performance results
gives the most appropriate indication of the Group's performance for the period under review and therefore commentaries
are presented on this basis unless otherwise stated.
In order to illustrate underlying performance, it is the Group's practice to discuss its results in terms of constant
exchange rate (CER) growth. This represents growth calculated as if the exchange rates used to determine the results
of overseas companies in sterling had remained unchanged from those used in the previous year. All commentaries are
presented in terms of CER unless otherwise stated.
The profit and loss account, statement of total recognised gains and losses and cash flow statement for the year ended,
and the balance sheet at, 31st December 2003 have been derived from the full Group accounts for that period, after
adjusting for the implementation of UITF 17 (revised) and UITF 38, which have been delivered to the Registrar of
Companies and on which the report of the auditors was unqualified and did not contain a statement under either section
237(2) or section 237(3) of the Companies Act 1985.
INVESTOR INFORMATION
Announcement of Q1 2004 Results
This Announcement was approved by the Board of Directors on Thursday 29th April 2004.
Financial calendar
The company will announce second quarter 2004 results on 27th July 2004. The second interim dividend for 2004 will
have an ex-dividend date of 4th August 2004 and a record date of 6th August 2004 and will be paid on 30th September
2004.
Annual General Meeting
The Annual General Meeting will be held at the Queen Elizabeth II Conference Centre, Broad Sanctuary, Westminster,
London SW1P 3EE on 17th May 2004.
Internet
This Announcement, and other information about GSK, is available on the company's website at: http://www.gsk.com.
This information is provided by RNS
The company news service from the London Stock Exchange
